NewEdge Wealth LLC acquired a new position in shares of Ventas, Inc. (NYSE:VTR - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 35,056 shares of the real estate investment trust's stock, valued at approximately $3,113,000.
Other institutional investors and hedge funds also recently modified their holdings of the company. Dynamic Wealth Strategies LLC acquired a new position in Ventas during the first quarter worth approximately $25,000. Meeder Asset Management Inc. acquired a new stake in Ventas during the 2nd quarter valued at $30,000. Wiser Advisor Group LLC acquired a new stake in Ventas during the 3rd quarter valued at $27,000. IFC & Insurance Marketing Inc. bought a new position in Ventas during the fourth quarter worth $30,000. Finally, Elyxium Wealth LLC bought a new position in Ventas during the fourth quarter worth $33,000. 94.18% of the stock is owned by institutional investors.
Ventas Stock Up 1.1%
Shares of NYSE:VTR opened at $92.82 on Friday. Ventas, Inc. has a 52-week low of $66.38 and a 52-week high of $101.60. The company has a market capitalization of $47.61 billion, a PE ratio of 171.89, a price-to-earnings-growth ratio of 2.12 and a beta of 0.69. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.44 and a current ratio of 0.44. The company has a fifty day moving average of $91.18 and a 200-day moving average of $87.04.
Ventas (NYSE:VTR - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The real estate investment trust reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.01. The firm had revenue of $1.73 billion during the quarter, compared to analysts' expectations of $1.68 billion. Ventas had a net margin of 4.08% and a return on equity of 1.99%. The company's revenue was up 21.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.87 EPS. On average, equities analysts predict that Ventas, Inc. will post 3.89 EPS for the current fiscal year.
Analysts Set New Price Targets
VTR has been the topic of several research analyst reports. Evercore reissued an "outperform" rating and issued a $95.00 price target on shares of Ventas in a report on Wednesday, April 29th. Wells Fargo & Company upped their target price on Ventas from $93.00 to $96.00 and gave the company an "overweight" rating in a research report on Monday, June 1st. UBS Group lifted their target price on Ventas from $85.00 to $93.00 and gave the stock a "neutral" rating in a report on Monday, May 4th. Scotiabank reduced their target price on shares of Ventas from $95.00 to $88.00 and set a "sector perform" rating for the company in a research report on Thursday, June 18th. Finally, Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a $100.00 price target on shares of Ventas in a research note on Tuesday, June 16th. Fifteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $98.00.
Get Our Latest Stock Report on VTR
Insider Activity at Ventas
In related news, Director Michael J. Embler purchased 2,500 shares of Ventas stock in a transaction on Wednesday, June 3rd. The stock was acquired at an average cost of $78.81 per share, for a total transaction of $197,025.00. Following the completion of the acquisition, the director owned 19,202 shares of the company's stock, valued at $1,513,309.62. This trade represents a 14.97% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.53% of the stock is currently owned by company insiders.
About Ventas
(
Free Report)
Ventas, Inc NYSE: VTR is a real estate investment trust (REIT) that specializes in healthcare-related real estate. The company acquires, owns and manages a diversified portfolio of properties serving the healthcare continuum, including senior housing communities, skilled nursing facilities, medical office buildings, life science and research centers, and other properties leased to healthcare providers and operators. Ventas generates revenue through long-term leases, property management and selective development activities focused on meeting the real estate needs of the healthcare sector.
Ventas' business model combines property ownership with active asset management and capital markets activity.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Ventas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ventas wasn't on the list.
While Ventas currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
